Learn how MSK helped a man with stage 4 stomach (gastric) cancer using checkpoint inhibitors, a type of immunotherapy that also treats many other cancers.
Learn about a new approach helping to reduce the risk of stomach and esophageal cancer coming back after surgery, which has been approved by the FDA thanks to a clinical trial with immunotherapy led by researchers at MSK.
Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial, a global phase three study, were presented today at the annual American Society of Clinical Oncology meeting and simultaneously published in the New England Journal of Medicine (NEJM).
